Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA v. Brown & Williamson Tobacco Corp.

This article was originally published in The Gray Sheet

Executive Summary

Supreme Court rules by a five-to-four margin March 21 that the Food Drug and Cosmetic Act does not authorize FDA to regulate tobacco products as medical devices. The FDCA allows FDA to regulate products that are unsafe for obtaining therapeutic benefit; but if tobacco products cannot be used safely for any therapeutic purpose, they fall outside of FDCA's regulatory scheme, the court concluded. Congressional action would be needed to grant FDA the explicit authority to regulate tobacco products. FDA's "nonsensical attempts" to regulate tobacco products as medical devices "was a colossal mistake from the beginning," Medical Device Manufacturers Association Executive Director Stephen Northrup comments in a same day release. It "would have set back the FDA's efforts to build a more reasonable regulatory structure for our industry's products at a time when the promise of medical technology has never been greater"

You may also be interested in...

FDA Officials Cite Reasons For Denying Application Reviews Over Data Integrity Breaches

Officials from the US Food and Drug Administration cited their reasons for refusing to review new applications for companies with unresolved data integrity failures.

Vaccinex Sees Mixed Signals In Huntington’s Study

However, Vaccinex sees possible efficacy for SEMA4D inhibition in later-stage Huntington’s as well as Alzheimer’s disease. Pepinemab is also being studied with Keytruda in head-and-neck cancer.

Approval Of BMS/Bluebird’s Ide-Cel May Come Just In Time

In last year’s acquisition, Bristol Myers Squibb agreed to pay Celgene investors another $9 per share based on three approvals, including idecabtagene vicleucel (bb2121) by 30 March 2021.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts